Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 1, 2005
Grant Date -
Aug 14, 2003
app pub date -
Aug 29, 2002
filing date -
Aug 31, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Disorders mediated by p38 kinase inhibitors are treated with compounds of the formula: ##STR1## or salts thereof, wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is substituted cycloalkyl, heterosubstituted cycloalkyl, helcroalkylsubstituted cycloalkyl, heterosubstituted cycloalkyl-alkly, heterocyclyl, heterocyclyl spiro cycloalkyl, aralkoxy, alkoxy, -alkylene-S(O).sub.n -alkyl (where is 1 or 2) or --SO.sub.2 Ar.sup.2 ; R.sup.3 is hydrogen, amino, monoalkylamino, dialkylamino, acylamino, --NR.sup.8 --C(.dbd.O)--R.sup.b (where R.sup.a is hydrogen or alkyl and R.sup.h is heterocyclyl or heteroalkyl), alkyl, cycloalkyl, phthalimidoalkyl, aryl, aralkyl, haloalkyl, heteroalkyl, cyanoalkyl, -alkylene-C(O) R (where R is hydrogen, alkyl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino) or acyl; and each of Ar.sup.1 and Ar.sup.2 is independently aryl.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully